Skip to main content
. 2023 Jul 26;13:12130. doi: 10.1038/s41598-023-39425-7

Figure 2.

Figure 2

Development and characterization of a cyst enriched-organoid. (a) Scheme of the development of a cyst enriched-organoid and the bright-field images of organoids. Scale bar = 100 µm. (b) The bright-field images of organoids derived from single cells prepared by day 4 conventional organoids and cyst-enriched organoids. Growth of the organoids was analyzed with CellTiter-Glo® 3D Cell Viability Assay and the bright-field image analysis by cellSens. Data represents mean ± s.d. (n = 3, biological replicates). Scale bar = 1 mm (c) The bright-field images of organoids in the growth factor reduced conditions and the results of the growth factor dependency analysis using CellTiter-Glo® 3D Cell Viability Assay. Scale bar = 100 µm. Data represents mean ± s.d. (n = 4, biological replicates). Δ means omitting a specific growth factor from the complete medium. (d) Whole mount immunostaining of cyst-enriched organoid for Sox9 (green) and F-actin (white), Ki-67 (red) and F-actin (white), merge with DAPI (blue), CK20 (green) and P-gp (red) with DAPI (blue), phospho-Ezrin (p-Ezrin, red) and DAPI (blue). Scale bar = 100 µm. **p < 0.01, ****p < 0.0001. Student t test for organoid formation assay, and Dunnett’s test compared with control for growth factor dependency analysis. W20% 20% Afamin/Wnt3a CM, E epidermal growth factor, N Noggin, R R-spondin 1, A A83-01, I IGF-1, F FGF-2, Y Y-27632, g Gastrin.